X
Novo Nordisk: survival of the fittest applies in diabetes and obesity market
https://pharmaphorum.com/views-and-analysis/novo-nordisk-survival-fittest-applies-diabetes-obesity-market/
Novo Nordisk
Novo hopes hypoglycaemia data will boost Tresiba
Lower severe hypo risk compared with Lantus – but no cardiac benefit.
AZ’s Bydureon disappoints in diabetes outcomes trial
Results give advantage to Boehringer/Lilly’s Jardiance.
Semaglutide could transform diabetes treatment, revive Novo Nordisk revenues
Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
Novo Nordisk board member quits over NASH conflict of interest
Mary Szela has quit to avoid a conflict of interest.
NICE rejects Orexigen weight loss pill
Body cites uncertainty over manufacturer’s data.
Keytruda in new lymphoma use leads latest CHMP decisions
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.